Navigation Links
Actemra Post-Launch Success Continues to Gain Momentum with Broader Adoption Compared to Biologic Analog Launches and a Professional Marketing Campaign That Resonates with Rheumatologists
Date:8/31/2010

EXTON, Pa., Aug. 31 /PRNewswire/ -- BioTrends has released the third and final wave of LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first humanized IL-6 receptor inhibitor agent approved for moderate-to-severe rheumatoid arthritis (RA) patients with an inadequate response to one or more TNF-alpha inhibitors. This report is derived from on-line survey responses from 75 rheumatologists and qualitative interviews with a subset of the survey respondents.

Rheumatologists report using Actemra with clinical success in patients who failed one or more TNF-alpha inhibitors despite the need for more frequent blood monitoring of liver function, lipid profile, and neutrophil and platelet counts. Each of these side effect issues has had varying degrees of impact on physicians' treatment patterns.

The breadth and depth of adoption of Actemra is greater than that of other biologic analogs in RA at a six-month post-launch timeframe. Patient origination is largely derived from the three established TNF-alpha inhibitors (Amgen/Pfizer's Enbrel, Abbott's Humira and Centocor Ortho Biotech's Remicade), although rheumatologists consider Actemra to compete more directly with (i.e., displace) Remicade and Bristol-Myers Squibb's Orencia.  

The core efficacy messages of Actemra's professional marketing campaign resonate strongly with rheumatologists. Based on a quantitative derived importance analysis supported by qualitative interviews with physicians, these core messages have a direct influence on physicians' perceptions of biologic performance in their clinical practice. In some instances, these efficacy attributes are competitive advantages for Actemra over other biologic agents.  

This study represents the final wave of LaunchTrends: Actemra. Trends are compared over time including trial and usage of Actemra, patient types, line of therapy, product perceptions, promotional detailing and messaging, and perceptions of manufacturers' co-pay assistance programs. Post-launch tracking of Actemra and the market dynamics for the biologic class will continue to be covered in the TreatmentTrends®: Rheumatoid Arthritis series and ChartTrends®: Biologics in Rheumatoid Arthritis, a 1,000+ patient chart review that compares actual treatment patterns with self-reported physician response.  

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.   For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research Group, Inc.Sharon Funk404-223-2963sfunk@bio-trends.comDecision Resources, Inc.Christopher Comfort781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Report by BioTrends Research Group To Highlight The Launch Of ACTEMRA (tocilizumab)
2. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
3. Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
4. Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
5. Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
6. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
7. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
8. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
9. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
10. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):